Iopamidol
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1985
- First approval year
- 1985
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Iopamidol
- Molecular weight
- 777.09
- Structure (SMILES)
- C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I
- iopamidol
- Iopamidol
- iopamidol 200
- iopamidol 250
- iopamidol 300
- iopamidol 370
- Iopamidol-200
- Iopamidol-250
- Iopamidol-300
- Iopamidol-370
- isovue
- Isovue
- isovue 128
- isovue 200
- isovue 250
- isovue 300
- isovue 370
- isovue m 200
- isovue m 300
- Isovue-128
- Isovue-200
- Isovue-250
- Isovue-300
- Isovue-370
- Isovue-m 200
And 5 more, listed on the interactive page.
- iopamidol
- Iopamidol
- Iopamidol [EP IMPURITY]
- Iopamidol [EP MONOGRAPH]
- Iopamidol [INN]
- Iopamidol [JAN]
- Iopamidol [MART.]
- Iopamidol [MI]
- Iopamidol [ORANGE BOOK]
- Iopamidol [USAN]
- Iopamidol [USP MONOGRAPH]
- Iopamidol [VANDF]
- Iopamidol [WHO-DD]
- Iopamidol 300 (Contrast)
- Iopamidol 370
- iopamidol ep impurity
- iopamidol ep monograph
- iopamidol inn
- iopamidol jan
- iopamidol mart
- iopamidol mi
- iopamidol orange book
- iopamidol usan
- iopamidol usp monograph
- iopamidol vandf
And 14 more, listed on the interactive page.
- ATC classification codes
- V08AB04
Sources for recorded values
- CAS registry numbers
- 60166-93-0
- ChEMBL ID
- CHEMBL1200932
- InChIKey
- XQZXYNRDCRIARQ-LURJTMIESA-N
- PubChem compound IDs
- 65492
- RxNorm IDs (RxCUI)
- 5966
- FDA ingredient codes (UNII)
- JR13W81H44
- Applicant
- BRACCO
- Approval date
- 31 Dec 1985
- Application number
- NDA018735
- Patents
- 0
- Designations
- 0
- Earliest recorded loss of exclusivity
- 10 Oct 2028
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Drug name stem
- io-
Administration routes
- Parenteral
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Glioma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005543
- Subject identifier
- D005910
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0008528
- Subject identifier
- D001749
- Condition
- Pituitary Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:1000979
- Subject identifier
- D010911
- Condition
- Breast Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition identifier
- EFO_0000319
- Condition identifier
- EFO_0000681
- Condition identifier
- EFO_0005543
- Condition identifier
- EFO_0008528
- Condition identifier
- EFO_1000979
- Condition identifier
- MONDO_0004995
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0006799
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0008315
- Condition identifier
- MONDO_0021042
- Highest recorded phase
- 4
- Event
- anaphylactic reaction
- Reports
- 123
- Reporting signal score
- 211.866
- Event
- anaphylactic shock
- Reports
- 92
- Reporting signal score
- 211.716
- Event
- anaphylactoid reaction
- Reports
- 66
- Reporting signal score
- 225.548
- Event
- arthralgia
- Reports
- 6
- Reporting signal score
- 21.7251
- Event
- blood pressure decreased
- Reports
- 47
- Reporting signal score
- 49.7907
- Event
- blood pressure immeasurable
- Reports
- 8
- Reporting signal score
- 21.1022
- Event
- cardiac arrest
- Reports
- 25
- Reporting signal score
- 22.3105
- Event
- cardio-respiratory arrest
- Reports
- 43
- Reporting signal score
- 104.785
- Event
- compartment syndrome
- Reports
- 12
- Reporting signal score
- 27.6924
- Event
- contrast encephalopathy
- Reports
- 15
- Reporting signal score
- 77.7582
- Event
- contrast media allergy
- Reports
- 31
- Reporting signal score
- 123.597
- Event
- contrast media reaction
- Reports
- 108
- Reporting signal score
- 506.243
- Event
- convulsion
- Reports
- 37
- Reporting signal score
- 22.4486
- Event
- depressed level of consciousness
- Reports
- 28
- Reporting signal score
- 20.8277
- Event
- diarrhoea
- Reports
- 14
- Reporting signal score
- 32.4811
- Event
- drug interaction
- Reports
- 1
- Reporting signal score
- 22.0136
- Event
- dyspnoea
- Reports
- 166
- Reporting signal score
- 66.8335
- Event
- electrocardiogram st segment elevation
- Reports
- 15
- Reporting signal score
- 32.3007
- Event
- erythema
- Reports
- 67
- Reporting signal score
- 39.0704
- Event
- extravasation
- Reports
- 54
- Reporting signal score
- 163.868
- Event
- fall
- Reports
- 4
- Reporting signal score
- 23.7127
- Event
- fatigue
- Reports
- 7
- Reporting signal score
- 50.231
- Event
- flushing
- Reports
- 37
- Reporting signal score
- 23.2585
- Event
- hepatic artery stenosis
- Reports
- 12
- Reporting signal score
- 61.9776
- Event
- hypersensitivity
- Reports
- 159
- Reporting signal score
- 203.637
And 17 more, listed on the interactive page.
- NCT03071328
- NCT04504331
- Discard unused portion after use
- Maintain in inverted position during use
- Maximum use time is 10 hours after puncture
- Penetrate container once with sterile system
- Storage temperature should not exceed 25°C (77°F)
- Swab container stopper with 70% isopropyl alcohol before opening
- Use aseptic technique
- Use only in designated radiological procedure rooms
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 8
- Polar surface area
- 188.45
- Calculated partition coefficient (ALogP)
- -1.01
- Calculated partition coefficient (XLogP)
- -2.4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 10
- Heavy atoms
- 31
- Molecular formula
- C17H22I3N3O8
- Monoisotopic mass
- 776.8541
- Natural product
- Yes
- 0270-1314
- 0270-1315
- 0270-1316
- 0270-1317
- 0270-1411
- 0270-1412
- 70436-124
- 70436-125
- 70436-126
- 70436-127
- 70436-211
- 70436-219
- Recorded assays
- 814
- Active assays
- 6
- Confirmatory
- Other
- Summary
- Contrast Media
Related records
Trials (91)
- 3 Tesla Magnetic Resonance Guided High Intensity Focused Ultrasound in the Treatment of Pain From Bone Metastases of Solid Tumors
- A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE)
- A Study of HCC High Risk Group Using Two Surveillance Tools
- A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography
- Accelerated Contrast-Enhanced High Resolution Whole Heart Cardiac MRI
- Adenosine Contrast CorrELations in Evaluating RevAscularizaTION
- Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis
- Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial
- Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan
- CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
- Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)
- CONTRAST (Can cONTrast Injection Better Approximate FFR compAred to Pure reSTing Physiology?)
- Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions
- Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity After Radiotherapy (XRT)
- Contrast Enhanced Ultrasound for Evaluation of Pediatric Abdominal Trauma
- Contrast Ultrasound Perfusion Imaging in PAD With Sonazoid
- Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging
- Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy
- Contrast-enhanced Ultrasound Evaluation of Chemoembolization
Approved for (2)
- Glioma
- Hypothalamic neoplasm
In development for (4)
- Breast cancer Phase 1
- Prostate cancer Early phase 1
- Renal cell carcinoma Early phase 1
- Urothelial carcinoma Early phase 1